Cargando…

Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review

Janus kinase (JAK) inhibitors have been developed as disease-modifying antirheumatic drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised regarding the risk of venous thromboembolism (VTE), such as deep vein thrombosis (DVT) and pulmonary embolism (PE). A rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mori, Shunsuke, Ogata, Fumihiko, Tsunoda, Ryusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458792/ https://www.ncbi.nlm.nih.gov/pubmed/34554329 http://dx.doi.org/10.1007/s10067-021-05911-4

Ejemplares similares

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis
por: Zhang, Juqi, et al.
Publicado: (2023)

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
por: Kotyla, Przemysław J., et al.
Publicado: (2020)

Changes in the cholesterol profile of patients with rheumatoid arthritis treated with biologics or Janus kinase inhibitors
por: Koh, Jung Hee, et al.
Publicado: (2023)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2023)

Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk
por: Rajasimhan, Suraj, et al.
Publicado: (2020)

Novel Potential Janus Kinase Inhibitors with Therapeutic Prospects in Rheumatoid Arthritis Addressed by In Silico Studies
por: Radu, Andrei-Flavius, et al.
Publicado: (2023)

Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
por: Ebina, Kosuke, et al.
Publicado: (2023)

Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia
por: Temmoku, Jumpei, et al.
Publicado: (2023)

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
por: Curtis, Jeffrey R, et al.
Publicado: (2016)

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population
por: Hall, Stephen, et al.
Publicado: (2018)

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
por: Dowty, Martin E., et al.
Publicado: (2019)

Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
por: Ebina, Kosuke, et al.
Publicado: (2022)

Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis
por: Wei, Qige, et al.
Publicado: (2023)

Janus kinase inhibitors effectively improve pain across different disease activity states in rheumatoid arthritis
por: De Stefano, Ludovico, et al.
Publicado: (2023)

Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune‐Mediated Inflammatory Diseases: A Systematic Review and Meta‐Analysis of Randomized Trials
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2022)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
por: Chen, Miao, et al.
Publicado: (2020)

Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses
por: Lomonte, Andrea B.V., et al.
Publicado: (2018)

The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis
por: Thudium, Christian S., et al.
Publicado: (2020)

Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US
por: Walton, Alison, et al.
Publicado: (2021)

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
por: Weitz, Jeffrey I, et al.
Publicado: (2022)

Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data
por: Min, Hong Ki, et al.
Publicado: (2023)

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
por: Milici, Anthony J, et al.
Publicado: (2008)

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
por: Harigai, Masayoshi, et al.
Publicado: (2020)

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
por: Fleischmann, Roy M, et al.
Publicado: (2021)

Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
por: Ochi, Sae, et al.
Publicado: (2022)

Association between Hematological Indicesand Disease Activity in Patients with Rheumatoid Arthritis Treated with Janus Kinase Inhibitors for 24 Weeks
por: Choe, Jung-Yoon, et al.
Publicado: (2022)

Are interferon-gamma release assays reliable to detect tuberculosis infection in patients with rheumatoid arthritis treated with Janus kinase inhibitors?
por: Scrivo, Rossana, et al.
Publicado: (2022)

Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies
por: Kumar, S. Sajith, et al.
Publicado: (2022)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Venous Thromboembolism in Rheumatoid Arthritis: The Added Effect of Disease Activity to Traditional Risk Factors
por: Omair, Mohammed A, et al.
Publicado: (2022)

The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis
por: Westerlind, Helga, et al.
Publicado: (2022)

Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
por: Kotyla, Przemysław J., et al.
Publicado: (2021)

Incidence of venous thromboembolism in rheumatoid arthritis, results from a “real-life” cohort and an appraisal of available literature
por: Conforti, Alessandro, et al.
Publicado: (2021)

Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany
por: Tony, Hans-Peter, et al.
Publicado: (2022)

The Janus kinase inhibitor (baricitinib) suppresses the rheumatoid arthritis active marker gliostatin/thymidine phosphorylase in human fibroblast-like synoviocytes
por: Joyo, Yuji, et al.
Publicado: (2022)

Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
por: Shamail, Ghazala M. H., et al.
Publicado: (2021)

Risk factors for venous thromboembolism and atherosclerotic cardiovascular disease: do they differ in patients with rheumatoid arthritis?
por: Ozen, Gulsen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kupdui1bhdc6bhudlaoqhqaqu8